Belite Bio Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	88.16	88.16	42.09	17.34	25.62
Cash & Cash Equivalents	88.16	88.16	42.09	17.34	25.62
Cash Growth	109.45%	109.45%	142.67%	-32.30%	-
Receivables	0.84	0.84	0	0	0
Other Current Assets	0.95	0.95	0.72	0.09	0.05
Total Current Assets	89.94	89.94	42.81	17.43	25.67
Property, Plant & Equipment	1.3	1.3	1.35	0.09	0.07
Other Long-Term Assets	3.4	3.4	0.12	0.82	0.01
Total Long-Term Assets	4.7	4.7	1.47	0.92	0.07
Total Assets	94.64	94.64	44.27	18.35	25.74
Accounts Payable	0	0	0	0.07	0.03
Current Debt	0.31	0.31	0.2	0	0
Other Current Liabilities	3.33	3.33	1.91	1.56	0.95
Total Current Liabilities	3.63	3.63	2.1	1.64	0.97
Long-Term Debt	0.58	0.58	0.67	0	0
Total Long-Term Liabilities	0.58	0.58	0.67	0	0
Total Liabilities	4.21	4.21	2.77	1.64	0.97
Total Debt	0.89	0.89	0.87	0	0
Debt Growth	2.31%	2.31%	-	-	-
Retained Earnings	-71.5	-71.5	-39.87	-27.22	-17.56
Comprehensive Income	-0.37	-0.37	-0.39	-0.2	-0.04
Shareholders' Equity	90.43	90.43	41.5	-15.09	-7.04
Net Cash / Debt	87.27	87.27	41.22	17.34	25.62
Net Cash / Debt Growth	111.70%	111.70%	137.68%	-32.30%	-
Net Cash Per Share	3.28	3.28	2.06	1.81	2.91
Working Capital	86.31	86.31	40.7	15.8	24.7
Book Value Per Share	3.40	3.40	2.08	-1.58	-0.80

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).